VAN-PANTOPRAZOLE TABLET (DELAYED-RELEASE)

البلد: كندا

اللغة: الإنجليزية

المصدر: Health Canada

العنصر النشط:

PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE)

متاح من:

VANC PHARMACEUTICALS INC

ATC رمز:

A02BC02

INN (الاسم الدولي):

PANTOPRAZOLE

جرعة:

40MG

الشكل الصيدلاني:

TABLET (DELAYED-RELEASE)

تركيب:

PANTOPRAZOLE (PANTOPRAZOLE SODIUM SESQUIHYDRATE) 40MG

طريقة التعاطي:

ORAL

الوحدات في الحزمة:

30/100/500

نوع الوصفة الطبية :

Prescription

المجال العلاجي:

PROTON-PUMP INHIBITORS

ملخص المنتج:

Active ingredient group (AIG) number: 0133229001; AHFS:

الوضع إذن:

CANCELLED POST MARKET

تاريخ الترخيص:

2019-08-07

خصائص المنتج

Page 1 of 39
PRODUCT MONOGRAPH
PR
VAN-PANTOPRAZOLE
Pantoprazole Sodium Delayed-Release Tablets, Manufacturer’s Standard
40 mg pantoprazole (as pantoprazole sodium sesquihydrate)
H
+
, K
+
- ATPase Inhibitor
MANUFACTURER AND DISTRIBUTOR:
Vanc Pharmaceuticals Inc.
Date of Preparation:
Building 152, 11782 River Road
September 23, 2014
Richmond, BC V6X 1Z7
www.vancpharm.com
Submission Control # 177608
Page 2 of 39
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL
INFORMATION ............................................................................
3
SUMMARY PRODUCT INFORMATION
..................................................................................................
3
INDICATIONS AND CLINICAL USE
.......................................................................................................
3
CONTRAINDICATIONS
.............................................................................................................................
4
WARNINGS AND PRECAUTIONS
...........................................................................................................
4
ADVERSE REACTIONS
.............................................................................................................................
6
DRUG INTERACTIONS
...........................................................................................................................
10
DOSAGE AND ADMINISTRATION
.......................................................................................................
12
OVERDOSAGE
..........................................................................................................................................
13
ACTION AND CLINICAL PHARMACOLOGY
......................................................................................
13
STORAGE AND STABILITY
...................................................................................................................
15
SPECIAL HANDLING INSTRUCTIONS
...............................................................................